List of Drospirenone drug patents
Drospirenone is owned by Exeltis Usa Inc.
Drospirenone contains Drospirenone.
Drospirenone has a total of 13 drug patents out of which 0 drug patents have expired.
Drospirenone was authorised for market use on 29 June, 2022.
Drospirenone is available in tablet, chewable;oral dosage forms.
Drospirenone can be used as prevention of pregnancy in females of reproductive age.
The generics of Drospirenone are possible to be released after 28 June, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603281 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
| US10849857 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
| US9603860 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
| US10179140 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
| US11413249 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US10987364 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11351122 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11291632 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11291633 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11123299 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11439598 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| US11478487 | EXELTIS USA INC | NA |
Jun, 2031
(8 years from now) | |
| US11504334 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jun 29, 2025 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Prevention of pregnancy in females of reproductive age
Dosage: TABLET, CHEWABLE;ORAL
DROSPIRENONE family patents
19
United States
5
European Union
4
Korea, Republic of
4
Lithuania
4
Hungary
3
Canada
3
Guatemala
3
Mexico
3
Ecuador
2
Spain
2
Denmark
2
RS
2
Poland
2
Brazil
2
Croatia
2
Peru
2
Portugal
2
Slovenia
1
Argentina
1
EA
1
Norway
1
Japan
1
New Zealand
1
Cyprus
1
Chile
1
Australia
1
South Africa
1
Colombia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic